Αρχική World News EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim World News EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim Από Ogkologos - 18 Σεπτεμβρίου, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR News digest – HPV vaccine, 1 million breast screenings missed and... 3 Οκτωβρίου, 2020 COVID-19 in people with cancer – what we know so far 4 Δεκεμβρίου, 2020 Saying YES: Inspiring a Diverse Generation of Cancer Scientists 8 Οκτωβρίου, 2020 New Drugs Raise Old Questions about Treating Cancer during Pregnancy 25 Μαΐου, 2022 Φόρτωση περισσοτέρων HOT NEWS Bra Straps with Disappearing Message Remind Women to Check Their Breasts... No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... European Lung Cancer Virtual Congress 2021, 25-27 March [Event Announcement] Study Finds That Gut Bacteria Could Be Used to Minimize Digestive...